Public Health Emergency - Leading a Nation Prepared
BARDA will support the advanced development of the new testing technology, known as host-response testing, under a 14-month contract with Inflammatrix Inc. The three diagnostic tests in development are for use on a point-of-care test system with results expected within 20-30 minutes.
Sepsis is a serious public health threat, killing approximately 270,000 Americans each year. BARDA is partnering with Cytovale to advance the development of a diagnostic that uses microfluidics, high-speed imaging, and machine learning to identify sepsis in less than 10 minutes! Rapid diagnosis can save lives and enhance health security in the U.S.
BARDA DRIVe is joining forces with Beckman Coulter Diagnostics to develop a digital diagnostic based on a machine-learning algorithm that may detect sepsis earlier. It will combine clinical data from lab tests and patient data from electronic health records in a predictive algorithm. Early detection of sepsis is essential to saving lives in emergency departments and other hospital settings.
Over 50 BARDA-supported medical countermeasures have been FDA licensed, cleared or approved. By cultivating unique partnerships with industry, BARDA has built a portfolio of medical countermeasures to strengthen health security.
OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease. The test will be used to detect the Ebola virus antigens in human blood from certain living individuals and from the oral fluids from certain recently deceased individuals suspected to have died from Ebola.
